Topical therapy of melanoma in Spain: Our Best Clinics and Costs 2025

His main areas of interest lie in the breast cancer field, in endocrine treatment, collaborating on studies aimed at overcoming resistance to hormone therapy that may occur both during adjuvant therapy and in metastatic disease. He has participated as a researcher in numerous phase 1, 2 and 3 studies, both in breast and melanoma, some of which have led to the approval of new drugs in new indications. He continues to work actively with other groups to drive the development of new drugs to help improve results in this patient group. In the field of melanoma, his main area of interest is centered on immunotherapy treatment. And along with all of the above there is patient care, always maintaining a holistic view of the patient, taking an interest in all the details that can happen in the evolution of their illness. Career Participant in trials that have led to the approval of cdk4/6 palbociclib and ribociclib inhibitors in the first line of metastatic breast cancer, as well as in developing trials for adjuvant disease. Participant in the studies that led to the approval of Pembrolizumab in the first line of metastatic melanoma, as well as the combination of Nivolumab and Ipilimumab, both of which revolutionized the treatment of this disease. Member of the Breast Cancer Unit and Melanoma Unit of the Vall d’Hebron University Hospital and the Vall d’Hebron Institute of Oncology (VHIO).